Lupus & antiphospholipid syndrome
Real world application of the 2023 ACR/EULAR antiphospholipid antibody syndrome classification criteria in a pharmacist directed anticoagulation clinic
Authors' conclusion
Results from this study indicate that APS continues to be a complex disease state with challenges in diagnosis and classification.
Study context
- Population
- Patients previously diagnosed with APS on anticoagulation managed by ambulatory care clinical pharmacists, single centrepreviously diagnosed APS
- Participants
- 51 participants
- Outcome
- Number of patients meeting 2023 ACR/EULAR APS classification criteria
Methodological detailssingle-centre, descriptive statistics
- Single-centre
- Descriptive statistics
Main finding
As reported in the abstract
Classification by 2023 ACR/EULAR APS criteria
Met classification criteria
12
23.5%
Did not meet classification criteria
33
64.7%
Insufficient data
6
11.7%
Observational data: associations, not effects.
Further findings
Reasons for not meeting criteria
- Did not meet laboratory criteria
- 13 (39.4%)
- Did not meet clinical criteria
- 6 (18.2%)
- Did not meet both laboratory and clinical criteria
- 14 (42.4%)
- Denominator printed as 27 patients that did not meet criteria
Antibody positivity among the 12 meeting criteria
- Triple positive
- 2 (16.7%)
- Double positive
- 3 (25%)
- Single positive
- 7 (58.3%)
Anticoagulation type
- Warfarin
- 42 (82.3%)
- Direct oral anticoagulants
- 4 (19%)
- Low molecular weight heparin
- 3 (5.8%)
- Fondaparinux
- 2 (3.9%)
Original publication
Real world application of the 2023 ACR/EULAR antiphospholipid antibody syndrome classification criteria in a pharmacist directed anticoagulation clinic. Lupus. Published 14 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →